Case Study: Drugs for Neglected Diseases Initiative achieves privacy-safe sharing of clinical trial data with Privacy Analytics

DNDi shares clinical trial data with Privacy Analytics after 20 years of neglected-disease research

The Drugs for Neglected Diseases initiative (DNDi) faced the challenge of sharing valuable clinical trial data for a vulnerable patient population co-infected with HIV and leishmaniasis. The data was highly sensitive as the patient group was small and geographically concentrated, making anonymization difficult without destroying the data's research value. DNDi engaged Privacy Analytics to safely anonymize the data for sharing in an infectious disease repository.

Privacy Analytics implemented its data anonymization service, conducting a detailed risk analysis and developing a tailored strategy to protect patient privacy. The solution preserved the data's utility for research, allowing DNDi to maximize the benefit of the clinical study. By making the anonymized data available, Privacy Analytics enabled other researchers to advance treatments and accelerate clinical trials for these neglected diseases, potentially saving lives.

Drugs for Neglected Diseases Initiative (DNDi)